Moreover, another recent study involving anti-inflammatory therapy with Canakinumab, a monoclonal antibody targeting interleukin-1β, demonstrated a reduction in recurrent cardiovascular events in patients with previous myocardial infarction and raised CRP but at a cost of more fatal infection (44). This evidence concerns the gene CRP and infection.